GLP-1 insurance coverage: why approval doesn't mean access

GLP-1 drugs approved specifically for chronic weight management face a coverage landscape meaningfully different from GLP-1 drugs approved for type 2 diabetes, even when it's the identical molecule — many commercial insurance plans and, notably, traditional Medicare have historically excluded coverage for weight-loss medications as a category, a policy that predates GLP-1 drugs but has become a much higher-stakes issue now that effective weight-loss drugs actually exist. Coverage for the same drug used for diabetes, heart failure, sleep apnea, or other now-approved indications is often more consistently available than coverage for the identical drug prescribed purely for weight management.

Employer-sponsored plans have taken sharply divergent approaches — some have added generous GLP-1 coverage as a recruiting and retention benefit given high employee demand, while others have tightened prior authorization requirements or dropped coverage entirely after seeing the actual cost impact of covering a drug class with sustained, long-term demand at list prices often exceeding a thousand dollars monthly. That inconsistency means two people with clinically similar profiles can have entirely different out-of-pocket costs based purely on which employer's plan they're on.

Where a drug has an additional FDA-approved indication beyond weight loss — cardiovascular risk reduction, sleep apnea, or now MASH liver disease among the growing list — patients and prescribers increasingly document that secondary indication specifically in prior authorization requests, since coverage denial rates tend to be measurably lower when the drug is billed under a covered medical indication rather than the weight-loss indication alone, even when the treatment goal for the patient is functionally the same.

For anyone facing a coverage denial, a formal appeal that includes specific clinical documentation — BMI, weight-related comorbidities, prior treatment attempts, and any additional approved indication that applies — meaningfully improves approval odds over an initial unappealed denial; manufacturer patient assistance and savings card programs are also worth checking directly, since list price and actual out-of-pocket cost for eligible patients can differ substantially.